On June 6, 2019 Innate Pharma SA (the "Company" – Euronext Paris: FR0010331421 – IPH) reported that it has enrolled the first patient in the TELLOMAK Phase II study of IPH4102 in patients with different subtypes of T-cell lymphoma (TCL) (Press release, Innate Pharma, JUN 6, 2019, View Source [SID1234536915]). IPH4102 is Innate Pharma’s wholly-owned first-in-class anti-KIR3DL2 antibody, developed for the treatment of T-cell lymphoma.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"The start of the TELLOMAK study is an important milestone in advancing IPH4102 towards potential registration in Sézary syndrome. The Phase I results demonstrated strong clinical activity, a favorable safety profile and a substantial improvement in quality of life. Based on these data, IPH4102 has the potential to become the treatment of choice in later lines of Sézary syndrome therapy, where there are currently limited effective treatment options and where toxicity is remaining an area of great concern with currently approved drugs", said Pierre Dodion, Chief Medical Officer of Innate Pharma. "Moreover, we are excited about exploring the activity of IPH4102 in larger subsets of T-cell lymphoma, such as Mycosis fungoides (MF) and Peripheral T-cell lymphoma (PTCL) where patients suffer from a significant medical need and to broaden the potential use of IPH4102."